Global Neuroendocrine Tumors Treatment Market

Neuroendocrine Tumors Treatment Market Size, Share, Growth Analysis, By Treatment Type(Somatostatin Analogy, Targeted Therapy), By End user(Hospitals, Clinics), By Indication(Gastric Neuroendocrine Tumors, Lung Neuroendocrine Tumors) - Industry Forecast 2024-2031


Report ID: SQSG35I2023 | Region: Global | Published Date: April, 2024
Pages: 165 | Tables: 90 | Figures: 76

Neuroendocrine Tumors Treatment Market Insights

Neuroendocrine Tumors Treatment Market size was valued at USD 1.57 billion in 2019 and is poised to grow from USD 1.7 billion in 2023 to USD 3.29 billion by 2031, growing at a CAGR of 8% in the forecast period (2024-2031).

The prevalence of cancers is rising significantly on a global scale. Rare tumors called neuroendocrine tumors (NET) develop from the cells of the neurological system and endocrine/hormonal system. Known as carcinoid tumors, neuroendocrine tumors typically develop in the gastrointestinal tract but can also develop in the appendix, rectum, pancreas, and lungs. Neuroendocrine tumors can either have a benign or cancerous nature.

Constipation, diarrhea, stomachaches, chronic coughing, low blood sugar, changes in blood pressure, heart problems, and other symptoms are all signs of neuroendocrine tumors. Rising neuroendocrine tumor prevalence, increased R&D spending, new product introductions, and early detection thanks to improved diagnostic methods are expected to accelerate the market for treatments for neuroendocrine tumors worldwide over the forecast period.

US Neuroendocrine Tumors Treatment Market is poised to grow at a sustainable CAGR for the next forecast year.

Market snapshot - 2024-2031

Global Market Size

USD 1.57 billion

Largest Segment

Hospitals

Fastest Growth

Hospitals

Growth Rate

8% CAGR

Global Neuroendocrine Tumors Treatment Market 2022-2028 ($ Bn)
Country Share for North America Region- 2021 (%)
Global Neuroendocrine Tumors Treatment Market Size By End-Use 2022-2028 ($ Bn)
Global Neuroendocrine Tumors Treatment Market Size By End-Use 2022-2028 (%)

To get more reports on the above market click here to Buy The Report

Neuroendocrine Tumors Treatment Market Segmental Analysis

The Global Neuroendocrine Tumors Treatment Market is segmented based on treatment type, end user, indication, and region. Based on treatment type, it is categorized into Somatostatin Analogy, Targeted Therapy, and Chemotherapy. Based on the end user, it is categorized into hospitals and clinics. Based on indication, it is categorized into Gastric Neuroendocrine Tumors, Lung Neuroendocrine Tumors, Pancreatic Neuroendocrine Tumors, and Appendicular Neuroendocrine Tumors. Based on region, it is categorized into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

Neuroendocrine Tumors Treatment Market Analysis by Treatment Type

On the basis of treatment type, Somatostatin analogues are anticipated to dominate the market by Treatment Type in the forecasted period , accounting for the largest percentage of the overall market revenue share. Innovative non-cytotoxic and novel cytotoxic drugs techniques are being developed for the treatment of cancer due to the limited efficacy and severe toxicity of conventional chemotherapy. Somatostatin analogues are among the many hormonal agents, and they are widely employed because they have promising results. It is widely used because of its innovative qualities, which helps the market flourish.

Neuroendocrine Tumors Treatment Market Analysis by Indication

On the basis of indications, stomach neuroendocrine tumors are expected to account for the largest percentage in the forecast period. Due to an unhealthy lifestyle and poor eating practices, patients may develop gastrointestinal carcinoid tumors, a cancer that develops in the lining of the GI tract. The rising popularity and demand, due to the increasing number of patients with stomach neuroendocrine tumors, has aided this segment in gaining the largest market share.

Neuroendocrine Tumors Treatment Market Analysis by End user

On the basis of end-user, hospitals are predicted to hold the largest proportion in the forecasted period. The rising market share of hospitals is caused by the rising demand for cancer detection and treatment as well as the large number of walk-in patients for a variety of ailments. They are also preferred by the patients due to factors such as easy access to a wide range of chronic illness treatments available in the hospitals and the emergency care facilities that are provided.

Global Neuroendocrine Tumors Treatment Market By End-Use, 2021 (%), 2023 (%)

To get detailed analysis on other segments, Request For Free Sample Report

Neuroendocrine Tumors Treatment Market Regional Insights

Based on region, North America is predicted to experience considerable growth in the neuroendocrine tumor treatment market, due to the increasing acceptance of novel neuroendocrine tumor treatments in the region. For instance, Ipsen's Somatuline Depot (lanreotide) Injection 120 mg was approved by the U.S. Food and Drug Administration (FDA) and it is intended for the treatment of adults with advanced or metastatic, moderately-differentiated, locally advanced, or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Because more medications are being approved by the European Commission (EC) for sale in European nations, the market for treating neuroendocrine tumors in Europe is anticipated to develop significantly over the course of the forecast period. For instance, the European Commission (EC) approved Lutathera (lutetium (177Lu) oxodotreotide) in September 2017 for the treatment of patients with progressive, well-differentiated, unresectable or metastatic gastroenteropancreatic neuroendocrine tumors that express the somatostatin receptor (GEP-NETs). With the exception of Iceland, Norway, and Liechtenstein, all 28 members of the European Union are now able to market Lutathera thanks to the authorisation.

Global Neuroendocrine Tumors Treatment Market By Geography, 2022-2028, 2024-2031
  • Largest
  • Fastest

To know more about the market opportunities by region and country, click here to
Buy The Complete Report

Neuroendocrine Tumors Treatment Market Dynamics

Neuroendocrine Tumors Treatment Market Drivers

  • A rise in the incidence of neuroendocrine tumors is expected to drive the market: The incidence and prevalence of neuroendocrine tumors (NET) are steadily rising worldwide, according to the data from the American Society of Clinical Oncology (ASCO). Because of this, the adoption rate of the medications for the treatment of this rare condition is aided by the rising prevalence of neuroendocrine tumors.
  • Extensive research and development to create new, focused medicines for NET management: Over the course of the projection period, the market is anticipated to rise as more medications are approved for the treatment for neuroendocrine tumors. For instance, the U.S. Food and Drug Administration (FDA) approved Advanced Accelerator Applications' new drug application (NDA) for Lutathera (lutetium Lu 177 dotatate) for the treatment of adults with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that are Somatostatin receptor positive, including foregut, midgut, and hindgut neuroendocrine tumors.

Neuroendocrine Tumors Treatment Market Restraints

  • The risk of side effects following treatment and the high cost of NET therapy are anticipated to hinder market expansion: Over the course of the projected period, the market expansion is anticipated to be hampered by the high cost of developing cures or pharmaceuticals and the adverse effects connected with the treatment. High blood sugar, the formation of gallstones, and moderate digestive system disturbances including bloating and nausea are among the potential adverse effects of therapies for neuroendocrine tumors.

Request Free Customization of this report to help us to meet your business objectives.

Neuroendocrine Tumors Treatment Market Competitive Landscape

Due to the presence of a sizable number of participants, the market is quite competitive. To increase their consumer base, the majority of businesses are engaging in strategic alliances like mergers and acquisitions. To draw in more customers, players are diversifying their product offerings.

Neuroendocrine Tumors Treatment Market Top Players Company Profiles

  • Novartis International AG
  • Pfizer Inc.
  • Ipsen Biopharmaceuticals, Inc.
  • Advanced Accelerator Applications (AAA)
  • F. Hoffmann-La Roche Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Exelixis, Inc.
  • Celgene Corporation
  • Amgen, Inc.
  • Merck & Co., Inc.
  • Mylan N.V.
  • Progenics Pharmaceuticals, Inc.
  • AbbVie, Inc.
  • Eisai Co., Ltd.
  • Ipsen Group
  • Curium Pharma
  • Ipsen S.A.
  • Endo Pharmaceuticals, Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Bayer AG

Neuroendocrine Tumors Treatment Market Recent Developments

  • In March 2021, The Journal of Nuclear Medicine published a new treatment, novel peptide receptor radionuclide therapy, for late stage neuroendocrine tumor that has been found to be more effective and have fewer side effects than the current treatments.

Neuroendocrine Tumors Treatment Key Market Trends

  • The neuroendocrine tumor treatment market is anticipated to be dominated by somatostatin analogs: As they limit tumor growth, symptoms, and biomarkers, somatostatin analogs (SSAs) are discovered to be the medications most frequently utilized to treat the neuroendocrine tumor. Due to the safe treatment methods provided by SSAs, they account for the greatest revenue share. Patients who are sensitive to radiotherapy and surgery are found to typically be treated with SSAs. Since many SSAs are presently in the clinical trial stage and awaiting approval, the market is anticipated to have rapid growth throughout the forecast period.

Neuroendocrine Tumors Treatment Market SkyQuest Analysis

SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Co-relates and Analyzes the Data collected by means of Primary Exploratory Research backed by the robust Secondary Desk research.

According to the analysis, the global neuroendocrine tumor treatment market is currently led by the countries in the North American region with Somatostatin analogues anticipated to dominate the market share, due to the more effective results associated with it, over the forecast period.

Report Metric Details
Market size value in 2023 USD 1.57 billion
Market size value in 2031 USD 3.29 billion
Growth Rate 8%
Forecast period 2024-2031
Forecast Unit (Value) USD Billion
Segments covered
  • Treatment Type
    • Somatostatin Analogy, Targeted Therapy, Chemotherapy
  • End user
    • Hospitals, Clinics
  • Indication
    • Gastric Neuroendocrine Tumors, Lung Neuroendocrine Tumors, Pancreatic Neuroendocrine Tumors, Appendicular Neuroendocrine Tumors
Regions covered North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA)
Companies covered
  • Novartis International AG
  • Pfizer Inc.
  • Ipsen Biopharmaceuticals, Inc.
  • Advanced Accelerator Applications (AAA)
  • F. Hoffmann-La Roche Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Exelixis, Inc.
  • Celgene Corporation
  • Amgen, Inc.
  • Merck & Co., Inc.
  • Mylan N.V.
  • Progenics Pharmaceuticals, Inc.
  • AbbVie, Inc.
  • Eisai Co., Ltd.
  • Ipsen Group
  • Curium Pharma
  • Ipsen S.A.
  • Endo Pharmaceuticals, Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Bayer AG
Customization scope

Free report customization with purchase. Customization includes:-

  • Segments by type, application, etc
  • Company profile
  • Market dynamics & outlook
  • Region

Historical Year 2019

To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.

Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share

Table Of Content

Executive Summary

Market overview

  • Exhibit: Executive Summary – Chart on Market Overview
  • Exhibit: Executive Summary – Data Table on Market Overview
  • Exhibit: Executive Summary – Chart on Neuroendocrine Tumors Treatment Market Characteristics
  • Exhibit: Executive Summary – Chart on Market by Geography
  • Exhibit: Executive Summary – Chart on Market Segmentation
  • Exhibit: Executive Summary – Chart on Incremental Growth
  • Exhibit: Executive Summary – Data Table on Incremental Growth
  • Exhibit: Executive Summary – Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • SWOT Analysis

KEY MARKET INSIGHTS

  • Technology Analysis
    • (Exhibit: Data Table: Name of technology and details)
  • Pricing Analysis
    • (Exhibit: Data Table: Name of technology and pricing details)
  • Supply Chain Analysis
    • (Exhibit: Detailed Supply Chain Presentation)
  • Value Chain Analysis
    • (Exhibit: Detailed Value Chain Presentation)
  • Ecosystem Of the Market
    • Exhibit: Parent Market Ecosystem Market Analysis
    • Exhibit: Market Characteristics of Parent Market
  • IP Analysis
    • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
  • Trade Analysis
    • (Exhibit: Data Table: Import and Export data details)
  • Startup Analysis
    • (Exhibit: Data Table: Emerging startups details)
  • Raw Material Analysis
    • (Exhibit: Data Table: Mapping of key raw materials)
  • Innovation Matrix
    • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
  • Pipeline product Analysis
    • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
  • Macroeconomic Indicators

COVID IMPACT

  • Introduction
  • Impact On Economy—scenario Assessment
    • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
  • Revised Market Size
    • Exhibit: Data Table on Neuroendocrine Tumors Treatment Market size and forecast 2021-2027 ($ million)
  • Impact Of COVID On Key Segments
    • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
  • COVID Strategies By Company
    • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • Regulatory Landscape
    • Exhibit: Data Table on regulation from different region
  • SWOT Analysis
  • Porters Analysis
    • Competitive rivalry
      • Exhibit: Competitive rivalry Impact of key factors, 2021
    • Threat of substitute products
      • Exhibit: Threat of Substitute Products Impact of key factors, 2021
    • Bargaining power of buyers
      • Exhibit: buyers bargaining power Impact of key factors, 2021
    • Threat of new entrants
      • Exhibit: Threat of new entrants Impact of key factors, 2021
    • Bargaining power of suppliers
      • Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
  • Skyquest special insights on future disruptions
    • Political Impact
    • Economic impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Market Size by Region

  • Chart on Market share by geography 2021-2027 (%)
  • Data Table on Market share by geography 2021-2027(%)
  • North America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • USA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Canada
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Europe
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Germany
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Spain
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • France
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • UK
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Europe
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Asia Pacific
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • China
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • India
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Japan
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Korea
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Asia Pacific
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Latin America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Brazil
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of South America
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Middle East & Africa (MEA)
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • GCC Countries
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Africa
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of MEA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

  • Competitive Landscape
    • Total number of companies covered
      • Exhibit: companies covered in the report, 2021
    • Top companies market positioning
      • Exhibit: company positioning matrix, 2021
    • Top companies market Share
      • Exhibit: Pie chart analysis on company market share, 2021(%)

Methodology

For the Neuroendocrine Tumors Treatment Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:

1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.

2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Neuroendocrine Tumors Treatment Market.

3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.

4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.

Analyst Support

Customization Options

With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Neuroendocrine Tumors Treatment Market:

Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.

Regional Analysis: Further analysis of the Neuroendocrine Tumors Treatment Market for additional countries.

Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.

Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.

Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.

Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.

Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.

Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Neuroendocrine Tumors Treatment Market size was valued at USD 1.57 billion in 2019 and is poised to grow from USD 1.7 billion in 2023 to USD 3.29 billion by 2031, growing at a CAGR of 8% in the forecast period (2024-2031).

Due to the presence of a sizable number of participants, the market is quite competitive. To increase their consumer base, the majority of businesses are engaging in strategic alliances like mergers and acquisitions. To draw in more customers, players are diversifying their product offerings. 'Novartis International AG', 'Pfizer Inc.', 'Ipsen Biopharmaceuticals, Inc.', 'Advanced Accelerator Applications (AAA)', 'F. Hoffmann-La Roche Ltd.', 'Teva Pharmaceutical Industries Ltd.', 'Exelixis, Inc.', 'Celgene Corporation', 'Amgen, Inc.', 'Merck & Co., Inc.', 'Mylan N.V.', 'Progenics Pharmaceuticals, Inc.', 'AbbVie, Inc.', 'Eisai Co., Ltd.', 'Ipsen Group', 'Curium Pharma', 'Ipsen S.A.', 'Endo Pharmaceuticals, Inc.', 'Spectrum Pharmaceuticals, Inc.', 'Bayer AG'

A rise in the incidence of neuroendocrine tumors is expected to drive the market: The incidence and prevalence of neuroendocrine tumors (NET) are steadily rising worldwide, according to the data from the American Society of Clinical Oncology (ASCO). Because of this, the adoption rate of the medications for the treatment of this rare condition is aided by the rising prevalence of neuroendocrine tumors.

The neuroendocrine tumor treatment market is anticipated to be dominated by somatostatin analogs: As they limit tumor growth, symptoms, and biomarkers, somatostatin analogs (SSAs) are discovered to be the medications most frequently utilized to treat the neuroendocrine tumor. Due to the safe treatment methods provided by SSAs, they account for the greatest revenue share. Patients who are sensitive to radiotherapy and surgery are found to typically be treated with SSAs. Since many SSAs are presently in the clinical trial stage and awaiting approval, the market is anticipated to have rapid growth throughout the forecast period.

Based on region, North America is predicted to experience considerable growth in the neuroendocrine tumor treatment market, due to the increasing acceptance of novel neuroendocrine tumor treatments in the region. For instance, Ipsen's Somatuline Depot (lanreotide) Injection 120 mg was approved by the U.S. Food and Drug Administration (FDA) and it is intended for the treatment of adults with advanced or metastatic, moderately-differentiated, locally advanced, or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Neuroendocrine Tumors Treatment Market

Product ID: SQSG35I2023

$5,300
BUY NOW GET FREE SAMPLE